VERACYTE INC (VCYT)
Health Care · diagnostic laboratories and genomic services · NASDAQ
Veracyte is a genomic diagnostics company transforming cancer care with advanced, high-value testing platforms across the patient journey from diagnosis to monitoring.
What VERACYTE INC does
Veracyte is a global diagnostics company that develops and commercializes advanced genomic tests aimed at helping physicians improve patient outcomes in the diagnosis and treatment of cancer. The company provides a portfolio of diagnostic products and services, including tests for thyroid, prostate, and breast cancer, as well as lung cancer classification, while expanding into minimal residual disease (MRD) detection. Veracyte operates by transitioning its tests from laboratory-developed tests (LDTs) to global in vitro diagnostic (IVD) offerings on multiple platforms.
Themes: genomic diagnostics, cancer diagnostics, minimal residual disease detection (MRD), precision medicine, oncology testing
Fundamentals
- Price$41.47 as of 2026-08-24 close
- Market cap$3.3B as of 2026-08-24
- 1-year return+33.8% 2025-08-22 close $31.00 → 2026-08-24 close $41.47
- P/E29.56 as of 2026-08-24
- Net margin+20.4% as of 2026-08-24
- Gross margin+71.7% as of 2026-08-24
- ROE+8.6% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+17.3% as of 2026-08-24
- Revenue CAGR (3y)+20.4% SEC XBRL
- Beta1.34 as of 2026-08-24
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How VCYT compares in its sector
- price-to-earnings ratiomiddle range 191 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
VCYT is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
30.1 #1640 of 1,704 scored · #231 of 240 in Health Care
Catalysts 49th: open-market insider buys in 90 days 10, the analyst consensus rating is unchanged since the prior reading; setup 45th: over the past year its closes ranged, and it has retraced a bit over half of its move over the past year — 59% of it; weakest is trend 14th: a strong downtrend, with sellers in control.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How VERACYTE INC looks technically
VERACYTE INC (VCYT) is trading 0.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 52 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 4 trading days ago. It is 30.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 0.2% below its 200-day average, the long-term trend line — a long-term downtrend | -0.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $52.41 | $52.41 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $42.40 | $42.40 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 54.25. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 52 trading days ago — a "golden cross", a bullish long-term signal | 52 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with sellers in control | 35.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30) | 36.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($40.09 to $47.96) — its "stochastic" reading is 28 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 28.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 34 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $60.91 | $60.91 |
|---|---|---|
| From the 52-week high | it is 30.5% below its 52-week high (its highest price of the past year) | -30.5% |
| Above the 52-week low | it is 49.8% above its 52-week low (its lowest price of the past year) | +49.8% |
| Below the 52-week high | it is 30.5% below its highest point of the past year | 30.5% |
| Since a 20-day breakout | it made a new 20-day low about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day low about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $86.03 (set on 2021-02-10) | $86.03 |
| Given back of the 52-week move | over the past year its closes ranged ($28.61 to $60.49), and it has given back a bit over half of its rise from last year’s low — 57% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $39.77 to $40.79. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 57.0% |
| From the all-time high | it is 50.8% below its all-time high | -50.8% |
| Nearest price level | it is trading 1.7% above a support level at $41.60 — a price it turned at five times since 2024-11-07, most recently on 2026-05-07. Since 2024-08-21 it has 13 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.7% |
| All-time low | its lowest closing price on record is $4.21 (set on 2016-03-24) | $4.21 |
| Above the all-time low | it is 905.0% above its all-time low | +905.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 94% of the past ~6 months) | 94th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.53 between its high and its low — about 6.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.53 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $35.86 and $57.55 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $35.86 – $46.71 – $57.55 |
| Typical daily range (% of price) | its price moves about 6.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.0% |
| Stretch from the 200-day average | it is sitting essentially on its 200-day average price (0.2% below it in plain percentage terms) | at its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.79× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a hammer | 2 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 2 sessions ago |
| Since a bearish engulfing | 7 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 7 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.9% |
|---|---|---|
| Open gap | it gapped 18.4% below the previous close 15 sessions ago and has not traded back through the level it left behind at 59.78 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -18.4% |
| Gap filled | a 3.1% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 31.3 percentage points (the stock lost 28.9% while the market gained 2.3%) | -31.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 9.5 percentage points (the stock lost 6.4% while the market gained 3.1%) | -9.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 7.7 percentage points (the stock gained 18.7% while the market gained 11.1%) | +7.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 23.3 percentage points (the stock gained 43.8% while the market gained 20.5%) | +23.3% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, trading below its 200-day average, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 8.1% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 22.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -8.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 3% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $43.62 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | -3.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% below the average price paid since it last reported on 2026-07-30 (its 8-K), so the typical buyer over that stretch is under water. That average is $45.34 — a volume-weighted average of daily closes over 17 sessions, not a true tick-by-tick VWAP. | -6.7% |
Price levels it has turned at before
VCYT last closed at $42.31 on 2026-08-21. Since 2024-08-21 it has turned at 13 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $41.60 | Support | 1.7% below the last close | turned there five times · 2024-11-07 to 2026-05-07 |
| $44.18 | Resistance | 4.4% above the last close | turned there twice · 2025-01-06 to 2025-12-22 |
| $40.14 | Support | 5.1% below the last close | turned there three times · 2025-01-14 to 2026-02-26 |
| $46.00 | Resistance | 8.7% above the last close | turned there four times · 2024-12-06 to 2026-06-12 |
| $37.80 | Support | 10.7% below the last close | turned there twice · 2025-10-27 to 2025-11-18 |
| $47.04 | Resistance | 11.2% above the last close | turned there twice · 2025-01-30 to 2026-01-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $54.25.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $47.27 and $51.95 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · beating the market · Printed a doji candle · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.67 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$57.82 range $44.00 – $70.00; median $55.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for VCYT
- Consensus EPS estimate$0.4127 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependency on continuous, timely, and adequate reimbursement from government and commercial payers for tests.","Risks associated with the reliance on single-source suppliers for quality reagents and raw materials.","Challenges and regulatory hurdles in the transition from LDTs to global IVD diagnostic platforms."]
What changed in the latest 10-Q
AI-assisted comparison of VCYT's 10-Q filed 2026-05-06 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to Annual Report on Form 10-K for year ended December 31, 2025 (newer filing filed 2026-05-06)
- Added language about 'predictive treatment decisions' and 'detection of disease recurrence' in Overview section (newer filing)
- Added statement about planning to offer Prosigna test as LDT in 2026 (newer filing)
- Added TrueMRD platform terminology alongside MRD platform (newer filing)
- Added reference to 'geopolitical challenges and other measures that restrict international trade' in Macroeconomic Factors (newer filing)
- Added 'weather-related disruptions' to seasonality impacts list (newer filing)
- Added 'and consumables' to supply chain challenges description (newer filing)
- Removed:
- Removed reference to Annual Report on Form 10-K for year ended December 31, 2024 (older filing filed 2025-11-05)
- Removed reference to Percepta Nasal Swab test being run in CLIA certified labs in support of clinical studies (older filing)
- Removed statement about future intention to offer 'Percepta Nasal Swab as IVD tests' (older filing)
- Removed reference to U.S. federal government shutdown since October 1, 2025 and its uncertain impact (older filing)
- Removed reference to regional conflicts 'between Russia and Ukraine and in Israel' phrasing (older filing changed to 'like those in the Middle East and between Russia and Ukraine')
- Reworded:
- Changed 'diagnostic, prognostic and treatment decisions' to 'diagnostic, prognostic and predictive treatment decisions, as well as the detection of disease recurrence' (newer filing)
- Changed 'laboratory developed tests' (LDTs spelled out) to abbreviated 'LDTs' (newer filing)
- Changed 'in vitro diagnostics, or IVD, tests' (IVD spelled out) to 'IVD tests' (newer filing)
- Changed 'primarily outside of the United States' to 'outside of the United States' (newer filing)
- Changed 'Our international distribution of IVDs is currently limited to our Prosigna test' to 'Our international distribution of IVDs is currently focused on our Prosigna test' (newer filing)
- Changed 'minimal residual disease, or MRD assays' to 'minimal residual disease, or MRD platform, TrueMRD platform, and our assays' (newer filing)
- Changed 'geopolitical challenges' scope from regional conflicts to 'geopolitical challenges and other measures that restrict international trade' (newer filing)
- Changed 'the U.S. federal government has been shut down since October 1, 2025' reference removed and 'macroeconomic effects of regional conflicts' language modified (newer filing)
- Changed phrasing from 'the Company's acquisition' to 'our acquisition' regarding C2i (newer filing)
- Changed 'quality of single-source reagents' to 'quality and supply of single-source reagents and consumables' (newer filing)
- Changed 'timing of industry conferences and timing of when patient deductibles are exceeded' to include 'weather-related disruptions' (newer filing)
- Notes:
- The older filing text appears truncated at the end of both sections, limiting full comparison of the complete 'Continued Adoption of and Reimbursement for our Products' section
- Some changes represent updates to forward-looking information based on filing date differences (2026-05-06 vs 2025-11-05)
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 8 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 8 sells ($8M) — 5 selling insiders
- Last 180 days0 buys · 12 sells ($10M) — 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-18. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about VCYT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 4 matched disclosures for VCYT from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
7 institutional 13F filers reported holding VCYT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 7
- Reported shares held 29,533,806
- Reported value $951,283,894
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 5 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
VCYT had 6,858,686 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
VCYT had 8.53% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.81 days to cover at the same settlement.
- Reported short interest (shares) 6,858,686
- Short interest (% of shares outstanding) 8.53%
- Prior settlement (shares) 6,674,331
- Reported change 2.76%
- Days to cover (reported) 4.81
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Exact Sciences (EXAS)
- Guardant Health (GH)
- Natera (NTRA)
- Illumina (ILMN)
- Thermo Fisher Scientific (TMO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare VCYT vs…
VERACYTE INC is found in…
Frequently asked questions
What does VERACYTE INC (VCYT) do?
Veracyte is a global diagnostics company that develops and commercializes advanced genomic tests aimed at helping physicians improve patient outcomes in the diagnosis and treatment of cancer. The company provides a portfolio of diagnostic products and services, including tests for thyroid, prostate, and breast cancer, as well as lung cancer classification, while expanding into minimal residual disease (MRD) detection.
What sector is VERACYTE INC (VCYT) in?
VERACYTE INC (VCYT) is classified in the Health Care sector. Its industry is diagnostic laboratories and genomic services. It trades on NASDAQ.
Who are VERACYTE INC's (VCYT) competitors?
Notable peers of VERACYTE INC (VCYT) include Exact Sciences, Guardant Health, Natera, Illumina and Thermo Fisher Scientific. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in VCYT?
Yes — we hold 4 matched STOCK Act disclosures for VCYT from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is VERACYTE INC (VCYT) overbought or oversold right now?
VERACYTE INC (VCYT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 36, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on VCYT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.